HD Focus

May 5, 2025 PDF Version – Study met primary endpoint with dose-dependent blood HTT protein lowering at Week 12 – – Favorable dose-dependent trends across clinical scales in Stage 2 […]

ASSEMBLEIA GERAL ORDINÁRIA A ABH – Associação Brasil Huntington, em cumprimento aos seus Estatutos, convoca seus associados e convida familiares, amigos, parceiros, colaboradores e a população em geral para participar da Assembleia Geral Ordinária a ser realizada: Dia: 17 de maio de 2025Horário: 8:30 h – Primeira Convocação9:00 h – Segunda ConvocaçãoLocal: ABH – Associação […]

O post Edital de Convocação – Assembleia Geral Ordinária apareceu primeiro em ABH - Associação Brasil Huntington.

Naša spoločnosť sa chce pripojiť ku kampani týkajúcej sa povedomia o Huntingtonovej chorobe ktorú zastrešuje Kanadská asociácia.  Toľko rokov bola Huntingtonova choroba (HCH), udržiavaná v tajnosti, kvôli stigme a diskriminácii. Kampaň #LightItUp4HD je skvelou príležitosťou pre ľudí s HCH zvýšiť povedomie o HCH a nadviazať kontakty, získať podporu od svojich komunít a napredovať s hrdosťou …

Rozsvietiť svetlá pre HCH Čítajte viac »

Imagine a vast and intricate factory, humming with activity. This factory isn’t manufacturing cars or electronics but rather the essential components that keep our bodies running. Inside each cell, thousands of tiny workers, known as proteins, perform highly specialized tasks. These proteins are responsible for everything from building cellular structures to sending messages and cleaning […]

FOR IMMEDIATE RELEASE Huntington’s Disease Awareness Month: A Month-Long Campaign to Educate and Empower This May, Celebrate and Raise Awareness...

The post Huntington’s Disease Awareness Month: A Month-Long Campaign to Educate and Empower This May, Celebrate and Raise Awareness with HDSA first appeared on Huntington's Disease Society of America.

Every May, communities around the world come together to shine a light on Huntington’s Disease (HD). From families and caregivers to clinicians, researchers, and advocates, we are united by one […]

You’re invited to take part in a powerful and creative project that gives voice to the lived experience...

May is Huntington’s Disease Awareness Month a time to uplift the voices of those impacted, challenge stigma, and spotlight the strength that lives within our community. For me, this month […]

La Dott.ssa Caterina MARIOTTI, neurologa presso l’Istituto Neurologico Carlo Besta di Milano, ha partecipato all’annuale Assemblea dei soci per un aggiornamento sugli studi clinici e sulle sperimentazioni farmacologiche, attualmente in corso presso il suo Istituto.

L'articolo Huntington | Ricerca e sperimentazioni: un impegno costante proviene da huntington-onlus.

Bella, an Advanced Breathwork Facilitator and Reiki Practitioner based in Sydney, knows the heavy silence that often surrounds...

HDBuzz has ramped up to match the accelerating pace of Huntington’s disease research. April 2025 brought us insight on somatic expansion, replacing lost brain cells, and clinical trial updates. Read on for the highlight reel from this month!

A new study shows that lowering MSH3, a key DNA repair protein, with antisense oligonucleotide (ASO) therapy can stop CAG repeat expansions in HD patient-derived brain cells. This could be a promising way to slow symptom onset and progression.

Aktualizácia 24.4.2025 Vyradením MSH3 proteínu pomocou ASO sa v darovaných mozgových bunkách podarilo zastaviť somatickú nestabilitu. Prekvapivým zistením, je že pri vyradení MSH3 sa výrazne spomalil nárast počtu opakovaní CAG. Testy prebiehali na geneticky upravených myšiach. Je niekoľko spoločností ktoré sa zameriavajú na znižovanie MSH3. Snáď sa dočkáme v relatívne krátkej dobe aj testoch na …

Somatická nestabilita Čítajte viac »

Farmaceut Roche kondigt aanpassingen aan in het GENERATION HD2-onderzoek op basis van een tussentijdse analyse. De studie gaat door, maar in de resterende duur zal alleen de dosis van 100 mg worden gebruikt. De dosis van 60 mg komt te vervallen.

De internationale farmaceut Roche heeft een update gegeven over de lopende klinische studie naar tominersen, een experimentele therapie die het huntingtine-eiwit verlaagt bij mensen met de ziekte van Huntington. Een onafhankelijke datamonitoringscommissie (iDMC), die toezicht houdt op de veiligheid en voortgang van het onderzoek, heeft geadviseerd om het onderzoek voort te zetten, met één belangrijke wijziging: voortaan wordt alleen de hogere dosis (100 mg) van het middel verder getest.

Two recent studies offer fresh insights into how antidepressants, often prescribed to help manage mood and anxiety, are prescribed in Huntington’s disease (HD) and might also influence cognitive decline. One study zooms in on medication use in HD, while the other takes a broader look at dementia and antidepressants. Together, they reveal a complex and evolving map of treatment decisions. But this doesn’t mean people living with HD should stop taking antidepressants. Let’s dig into why that is.

Evolving HD Medication Landscape

The first study examined medication use among people with HD, using data from thousands of people in Enroll-HD, the largest observational study of the disease. Among other things, Enroll-HD collects data on what medications are most commonly used during HD care. One striking finding? A staggering 84% of people with HD use at least one medication, with this number climbing as the disease progresses.

In the early stages, people with HD take an average of 2.5 medications. But as the disease advances, that number more than doubles to 5.2. This really highlights just how much a person’s medical needs change as HD progresses.

Farmaceut Roche kondigt aanpassingen aan in het GENERATION HD2-onderzoek op basis van een tussentijdse analyse. De studie gaat door, maar in de resterende duur zal alleen de dosis van 100 mg worden gebruikt. De dosis van 60 mg komt te vervallen.

De internationale farmaceut Roche heeft een update gegeven over de lopende klinische studie naar tominersen, een experimentele therapie die het huntingtine-eiwit verlaagt bij mensen met de ziekte van Huntington. Een onafhankelijke datamonitoringscommissie (iDMC), die toezicht houdt op de veiligheid en voortgang van het onderzoek, heeft geadviseerd om het onderzoek voort te zetten, met één belangrijke wijziging: voortaan wordt alleen de hogere dosis (100 mg) van het middel verder getest.

Two recent studies offer fresh insights into how antidepressants, often prescribed to help manage mood and anxiety, are prescribed in Huntington’s disease (HD) and might also influence cognitive decline. One study zooms in on medication use in HD, while the other takes a broader look at dementia and antidepressants. Together, they reveal a complex and […]